A few days ago, a piece of news about the draft version of the US "Biosafety Act" stirred the-share biomedical sector, and the share prices of many companies suffered a sharp drop. Related companies have issued clarification announcements.

following the emergency response of yaoming kant (rights protection) on the evening of January 26, yaoming biology (688046) and huada zhizao (688114) also issued clarification announcements on the evening of January 28.

Huada Zhizao said that the company has noticed that the draft is still in the proposal stage, and there are many factual errors in the company's allegations, which may be revised or terminated in the future, and there is still great uncertainty about whether the law can be formed.

Huada Zhizao said that in the process of development, the company strictly abides by the laws and regulations of the place where the market is operated, and pays great attention to data security and privacy protection. As an upstream equipment provider in the gene sequencing industry, the company's business processes do not involve data collection, and the data generated by customers based on the company's sequencing platform are collected, stored, processed and controlled by the customers themselves.

Yaokang Biology said that the company is a high-tech enterprise specializing in the research and development, production, sales and related technical services of experimental animal mouse models, providing customers with commercialized mouse models with independent intellectual property rights, and at the same time carrying out model customization, Customized breeding, functional efficacy analysis and other one-stop services, to meet the needs of customers in the field of basic research and new drug development, such as disease mechanism analysis, drug target discovery, efficacy screening and verification, and experimental animal mouse models.

"The company's model animals and mice are all produced using human genome sequences with no species differences published by the scientific research community, and do not involve any human source gene sequence analysis business." Yaokang Bio declares that all of the company's technologies and samples are publicly available resources or commercially purchased resources in the scientific research community and are not within the scope of the draft Biosafety Act.

yaokang biology specially mentioned that since the draft has not yet come into effect and promulgated, the relevant contents still need further deliberation and there is the possibility of change. The company will also closely monitor the progress of the draft legislative process. At present, the production and operation of the company and its subsidiaries are all normal and orderly. At the same time, the company will also pay attention to changes in the external environment in a timely manner to ensure the steady growth of the company's business.

According to previous media reports, on January 26, the industry circulated that the United States intends to introduce the "Biosafety Act" to ensure that foreign biotechnology companies cannot obtain funds from American taxpayers. Once passed, the bill would restrict federally funded medical facilities from using foreign rival biotech companies, including BGI Group and its subsidiaries BGI and Complete Genomics, and another Chinese company, WuXi AppTec.

when the market opened in the afternoon of that day, the "yaoming department" led a group of CXO and innovative drug sectors to flash down. among them, yaoming kant's share price fell by 3.02 and 5.36 respectively, while other stocks such as tiger medicine, kanglong chemical industry and yaokang biology also suffered heavy losses, all falling by more than 10%, yaokang biology fell by 11.01 on that day, and its share price closed at 13.98 yuan/share.

on the evening of January 26, yaoming kant held an urgent telephone conference on the "proposal circulated in the industry" and issued a clarification announcement.

WuXi AppTec stated that the draft biosecurity law has not yet taken effect and the subsequent legislative process requires the U.S. House of Representatives and the U.S. Senate to vote on their respective versions of the bill after review by the relevant committees to form the final version. Therefore, the content of the draft biosecurity law is still subject to further consideration and possible changes.

WuXi AppTec said that the company is closely monitoring the progress of the legislative process of the draft with consultants. The Company notes that the draft Biosafety Law contains information about WuXi AppTec, which it believes is neither appropriate nor accurate. The Company firmly believes that WuXi AppTec's business development does not pose a risk to the security of any country. The Company always complies with the laws and regulations of the countries in which it operates, including China and the United States. For more than two decades, WuXi AppTec has been a trusted partner in the global healthcare industry, providing drug development and manufacturing services to thousands of U.S. and global customers, helping to promote the early launch of innovative drugs.

Huada Gene responded that the company's management is evaluating the incident, but does not believe that the company's stock price trend on that day is directly related to the bill. The possibility of the bill is mainly based on the position of relevant parties in the United States. Make an evaluation.

Sina statement: This news is reprinted from Sina's cooperative media. Sina posted this article for the purpose of conveying more information, and does not mean that it agrees with its views or confirms its description. The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.